Effects of acute-liver-failure-plasma exposure on hepatic functionality of HepaRG-AMC-Bioartificial Liver

被引:15
|
作者
Nibourg, Geert A. A. [1 ,2 ]
Hoekstra, Ruurdtje [1 ,2 ]
van der Hoeven, Tessa V. [1 ,2 ]
Ackermans, Mariette T. [3 ]
Hakvoort, Theodorus B. M. [2 ]
van Gulik, Thomas M. [1 ]
Chamuleau, Robert A. F. M. [2 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Surg, Surg Lab, NL-1105 Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Endocrinol, NL-1105 Amsterdam, Netherlands
关键词
AMC-BAL; fulminant hepatic failure; liver assist device; liver support; toxicity; CELL-LINE; HEPATOCYTE FUNCTION; GENE-EXPRESSION; HEPG2; CELLS; SERUM; OVEREXPRESSION; CYTOTOXICITY; METABOLISM; DEVICES; GROWTH;
D O I
10.1111/liv.12090
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims The AMC-bioartificial liver loaded with the human hepatoma cell line HepaRG as biocomponent (HepaRG-AMC-BAL) has recently proven efficacious in rats with acute liver failure (ALF). However, its efficacy may be affected by cytotoxic components of ALF plasma during treatment. In this study, we investigated the effects of ALF-plasma on the HepaRG-AMC-BAL. Methods HepaRG-AMC-BALs were connected to the blood circulation of rats with total liver ischaemia, either during the first 5h after induction of ischaemia (mild ALF group), or during the following 10h (severe ALF group). After disconnection, the BALs were assessed for cell leakage, gene transcript levels, ammonia elimination, urea production, cytochrome P450 3A4 activity, apolipoprotein A 1 production, glucose and amino acid metabolism. Results Cell leakage increased 2.5-fold in the severe ALF group, but remained limited in all groups. Hepatic gene transcript levels decreased (max 40-fold) or remained stable. In contrast, hepatic functions increased slightly or remained stable. Particularly, urea production increased 1.5-fold, with a concurrent increase in arginase 2 transcription and arginine consumption, with a trend towards reduced conversion of ammonia into urea. The amino acid consumption increased, however, the net glucose consumption remained stable. Conclusions The HepaRG-AMC-BAL retains functionality after both mild and severe exposure to ALF plasma, but urea production may be increasingly derived from arginase 2 activity instead of urea cycle activity. Nevertheless, the increase in cell leakage and decrease in various hepatic transcript levels suggest that a decrease in hepatic functionality may follow upon extended exposure to ALF plasma.
引用
收藏
页码:516 / 524
页数:9
相关论文
共 50 条
  • [31] Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients
    Morsiani, E
    Pazzi, P
    Puviani, AC
    Brogli, M
    Valieri, L
    Gorini, P
    Scoletta, P
    Marangoni, E
    Ragazzi, R
    Azzena, G
    Frazzoli, E
    Di Luca, D
    Cassai, E
    Lombardi, G
    Cavallari, A
    Faenza, S
    Pasetto, A
    Girardis, M
    Jovine, E
    Pinna, AD
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2002, 25 (03): : 192 - 202
  • [32] HepaRG-Progenitor Cell Derived Hepatocytes Cultured in Bioartificial Livers Are Protected from Healthy- and Acute Liver Failure-Plasma Induced Toxicity
    van Wenum, Martien
    Treskes, Philipp
    Adam, Aziza A. A.
    van der Mark, Vincent. A.
    Jongejan, Aldo
    Moerland, Perry D.
    van Gulik, Thomas M.
    Elferink, Ronald P. J. Oude
    Chamuleau, Robert A. F. M.
    Hoekstra, Ruurdtje
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 48 (05) : 2189 - 2204
  • [33] Activation of hepatic stellate cells in liver tissue of patients with fulminant liver failure after treatment with bioartificial liver
    Petrovic, LM
    Arkadopoulos, N
    Demetriou, AA
    HUMAN PATHOLOGY, 2001, 32 (12) : 1371 - 1375
  • [34] Successful pregnancy after porcine bioartificial liver treatment and liver transplantation for fulminant hepatic failure
    Nyberg, SL
    Hay, EJ
    Ramin, KD
    Rosen, CB
    LIVER TRANSPLANTATION, 2002, 8 (02) : 169 - 170
  • [35] Bioartificial liver support for acute liver failure.: First case treated in Spain
    Salmerón, JM
    Lozano, M
    Agustí, E
    Mas, A
    Mazzara, R
    Marín, P
    Ordinas, A
    Rodés, J
    MEDICINA CLINICA, 2001, 117 (20): : 781 - 784
  • [36] The development of a new bioartificial liver and its application in 12 acute liver failure patients
    Ding, YT
    Qiu, YD
    Chen, Z
    Xu, QX
    Zhang, HY
    Tang, Q
    Yu, DC
    WORLD JOURNAL OF GASTROENTEROLOGY, 2003, 9 (04) : 829 - 832
  • [37] HYBRID BIOARTIFICIAL LIVER IN HEPATIC-FAILURE - PRELIMINARY CLINICAL REPORT
    MATSUMURA, KN
    GUEVARA, GR
    HUSTON, H
    HAMILTON, WL
    RIKIMARU, M
    YAMASAKI, G
    MATSUMURA, MS
    SURGERY, 1987, 101 (01) : 99 - 103
  • [38] Standardization of ischemic hepatic failure in pigs as a model for bioartificial liver assessment
    Miyashita, T
    Enosawa, S
    Tanaka, H
    Tamura, A
    Amemiya, H
    Aoki, T
    Koyanagi, Y
    Suzuki, S
    SURGERY TODAY, 2003, 33 (10) : 743 - 750
  • [39] Standardization of Ischemic Hepatic Failure in Pigs as a Model for Bioartificial Liver Assessment
    Tomoyuki Miyashita
    Shin Enosawa
    Hideaki Tanaka
    Akihiko Tamura
    Hiroshi Amemiya
    Tatsuya Aoki
    Yasuhisa Koyanagi
    Seiichi Suzuki
    Surgery Today, 2003, 33 : 743 - 750
  • [40] Treatment of acetaminophen-induced fulminant hepatic failure with a bioartificial liver
    Watanabe, FD
    Shackleton, CR
    Cohen, SM
    Goldman, DE
    Arnaout, WS
    Hewitt, W
    Colquhoun, SD
    Fong, TL
    Vierling, JM
    Busuttil, RW
    Demetriou, AA
    TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) : 487 - 488